A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma

BACKGROUND: This phase 2 study evaluated trebananib (AMG 386), an investigational peptide-Fc fusion protein that neutralises the interaction between angiopoietins-1/2 and the Tie2 receptor, plus FOLFIRI as second-line treatment for patients with metastatic colorectal cancer. METHODS: Patients had ad...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Peeters, M, Strickland, A H, Lichinitser, M, Suresh, A V S, Manikhas, G, Shapiro, J, Rogowski, W, Huang, X, Wu, B, Warner, D, Jain, R, Tebbutt, N C
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2013
Témata:
Clinical Study
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3593550/
https://ncbi.nlm.nih.gov/pubmed/23361051
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.594
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky